Paying users zone. Data is hidden behind hidden.

  • Get 1-month access to Bristol-Myers Squibb Co. for $17.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Microsoft Excel LibreOffice Calc

Bristol-Myers Squibb Co. (BMY)


Balance Sheet: Assets

Low level of difficulty

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Assets are resources controlled by the company as a result of past events and from which future economic benefits are expected to flow to the entity.

Bristol-Myers Squibb Co., consolidated balance sheet: assets

US$ in millions

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Cash and cash equivalents hidden hidden hidden hidden hidden
Marketable securities hidden hidden hidden hidden hidden
Net trade receivables hidden hidden hidden hidden hidden
Alliance receivables hidden hidden hidden hidden hidden
Prepaid and refundable income taxes hidden hidden hidden hidden hidden
Royalties, VAT and other hidden hidden hidden hidden hidden
Receivables hidden hidden hidden hidden hidden
Inventories hidden hidden hidden hidden hidden
Deferred income taxes hidden hidden hidden hidden hidden
Prepaid expenses and other hidden hidden hidden hidden hidden
Current assets hidden hidden hidden hidden hidden
Property, plant and equipment hidden hidden hidden hidden hidden
Goodwill hidden hidden hidden hidden hidden
Other intangible assets hidden hidden hidden hidden hidden
Deferred income taxes hidden hidden hidden hidden hidden
Marketable securities hidden hidden hidden hidden hidden
Other assets hidden hidden hidden hidden hidden
Non-current assets hidden hidden hidden hidden hidden
Total assets hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-25), 10-K (filing date: 2018-02-13), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-12), 10-K (filing date: 2015-02-13).


Assets: Selected Items

Balance sheet item Description The company
Current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co.’s current assets increased from 2016 to 2017 and from 2017 to 2018.
Property, plant and equipment Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. Bristol-Myers Squibb Co.’s property, plant and equipment increased from 2016 to 2017 and from 2017 to 2018.
Non-current assets Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Bristol-Myers Squibb Co.’s non-current assets declined from 2016 to 2017 and from 2017 to 2018.
Total assets Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. Bristol-Myers Squibb Co.’s total assets declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.

Current Assets: Selected Items

Balance sheet item Description The company
Cash and cash equivalents Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. Bristol-Myers Squibb Co.’s cash and cash equivalents increased from 2016 to 2017 and from 2017 to 2018.
Marketable securities Amount of investment in marketable security, classified as current. Bristol-Myers Squibb Co.’s marketable securities declined from 2016 to 2017 but then increased from 2017 to 2018 not reaching 2016 level.
Net trade receivables Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. Bristol-Myers Squibb Co.’s net trade receivables increased from 2016 to 2017 and from 2017 to 2018.
Inventories Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. Bristol-Myers Squibb Co.’s inventories declined from 2016 to 2017 but then slightly increased from 2017 to 2018.